ICAM1 and neoplasm: The possible mechanisms include 1) targeted accumulation and site‐specific release of cytotoxic drugs; 2) blocking the inhibitory signaling pathway of B7‐H3‐CD3, suppressing tumor immune evasion, improving the T‐cell response, and synergizing with ICAM‐1–Dxd to enhance efficacy; and 3) inducing immunogenic cell death, in which tumor cells produce natural tumor‐associated antigens and release DAMPs, which interact with pattern recognition receptors on the surface of DCs, activating the immune response and reprogramming the TIM.